Feature | March 16, 2008| Cristen C. Bolan

Web Exclusive: SCAI to Deliver New Valve Therapy Data at SCAI-ACCi2

The Society for Cardiovascular Angiography and Interventions (SCAI) has partnered with the American College of Cardiology (ACC) to co-locate its 33rd annual meeting with the ACC.08 57th Annual Scientific Session to form the new SCAI-ACCi2 meeting.

The SCAI plans to provide as always the same practical, take-home messages for the dedicated interventional cardiologist even in this larger setting. President of The Society for Cardiovascular Angiography and Interventions, Bonnie H. Weiner, M.D., MSEC, MBA, FSCAI, explained exactly how in an interview with Diagnostic & Invasive Cardiology (DAIC).

DAIC: This year you have combined SCAI’s Annual Scientific Sessions with the ACC’s Innovation in Intervention: i2 Summit. Why and how did you go about combining these two programs?

Dr. Weiner: The best way for us to deliver a single spring meeting in Interventional Cardiology in 2008 was to co-locate our meeting with the ACC.
This allows us to take advantage of some of the things [ACC] already had planned as well as some of the things we already had planned at the time we decided to embark on the project. ACC had already planned the live cases, for example, and it made sense to utilize some, if not all, of what had already been discussed in that context.
Our goal is, and the tradition of our meeting is, to provide practical, take-home messages for the dedicated interventional cardiologist, and we wanted to maintain that message and that opportunity for the attendees within this larger context. What we brought to the meeting with SCAI includes our traditional Hildner and Founders’ Lectures. In addition, we have added a new a congenital heart disease lecture and an international lecture. All of these are part of the tradition and value of meeting, as is the hemodynamic symposium and the Judkins Imaging Symposium. The attendees can also take advantage of what i2 Summit has traditionally done, such as live cases.
This is our annual meeting in March, and it represents our identity as an organization and, yes, it’s also in partnership with ACC this year.

DAIC: What are some of the most important trends developing in interventional cardiology?

Dr. Weiner: We continue to refine the technologies and learned more about drug-eluting stents and are looking forward to the products that will reach the market in the U.S. this year.
We are also looking at the importance of ischemia, rather than just anatomy in the context of revascularization. A lot of the clinical trials done up to this point really have not addressed that issue, and we are looking at analyses that will refine that kind of indication for intervention, which is really at the crux of what we do to take care of patients. There is also new and interesting information on new percutaneous valve therapy, and new hybrid approaches to treating other structural heart disease, particularly congenital heart disease.

DAIC: What are some the sessions you would like to highlight for interventional cardiologists and in particular SCAI members?

Dr. Weiner: Again, the Judkins Imaging Symposium and the Hemodynamic Symposium. We will have late-breaking clinical trials, which will be extraordinarily interesting. There are additional analyses from studies that have previously been reported about drug-eluting stents and treatment of myocardial infarction and new drugs for adjunctive use in those areas.
There is a session on the business of medicine – in the sense of the regulatory environment and aligning hospitals and physicians to optimize patient care. There are peripheral vascular disease sessions that will showcase new information in the treatment of these complex patients.
There is also expanded use of simulation as a learning and teaching tool – such as the 360-degree theatre for demonstration activities and hands-on activity. Also, there is new technology looking at therapy for carotid disease and stroke for intracranial disease.
All of these things add to our knowledge and the evidence we use to decide what the best therapy for an individual patient is.

DAIC: How will you recreate the intimate setting of the SCAI Annual Scientific Session in the SCAI-ACCi2 meeting?

Dr. Weiner: We are doing that as much as possible. Remember, we are now in an environment of 30,000 people, and a much bigger exhibit hall, but we are going to try to do that. We have receptions scheduled in the exhibit hall, and in the interventional pavilion, the Presidents’ reception. We are still having the SCAI Annual Banquet and are trying to encourage people to network and interact not only with the speakers but also with their colleagues. Many of the most interesting events at our meetings happen in the hallways.

For those who previously attended the SCAI Annual Scientific Sessions, this is going to be a great meeting and, within this context, is going to be as much as that same experience as we can. For those who have never attend an SCAI meeting, it’s an opportunity to get to know us better.

Related Content

Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
4Tech, TriCinch TTVR, transcather tricuspid valve repair device, first implant
News | Heart Valve Technology| September 22, 2016
4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter...
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50

Transesophageal echo (TEE) has become an essential part of the new transcatheter structrual heart therapies, giving rise to a new sub-speciality of interventional echocardiography.  

Feature | Cath Lab Navigation Aids| September 21, 2016 | Dave Fornell
The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as a
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Edwards sapien, intermediate risk patients, CE mark
News | Heart Valve Technology| September 20, 2016
September 19, 2016 — Edwards Lifesciences received European CE mark to expand use of the Edwards Sapien 3 transcathet
Valtech Cardio, Cardioband Tricuspid, Cardioband Mitral, PCR London Valves 2016, study data
News | Heart Valve Technology| September 19, 2016
Valtech Cardio Ltd. announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at...
Lotus Edge Valve, CE mark, boston scientific, TAVR, TAVI

The Lotus Edge system in its deployed position. The Lotus valve expands outward as it is compressed and buckled in the deployment position. It also has a skirt to help eliminate paravalvular leaks.

News | Heart Valve Technology| September 19, 2016
September 19, 2016 — Boston Scientific received European CE mark approval for its Lotus Edge Valve System, the compan
News | Venous Therapies| September 12, 2016
Veniti Inc. has closed on $25 million in Series D equity financing from Boston Scientific Corp. The funds will allow...
Xeltis bioabsorbable aortic conduit, endogenous tissue restoration, ETR, preclinical data, ISACB 2016
News | Heart Valve Technology| September 09, 2016
Six-month preclinical data from trials of a Xeltis bioabsorbable aortic conduit were presented at the 2016 scientific...
Overlay Init